Sign in Subscribe
Nanotechnology

Advances in Pulmonary Drug Delivery: PLGA Nanoparticles Show Promise

Strategic Insights

— 2 min read

Research at the Federal University of Juiz de Fora has highlighted the potential of poly(lactic-glycolic acid) (PLGA) nanoparticles in enhancing pulmonary drug delivery. The study emphasizes the need for more effective therapeutic approaches to combat pulmonary diseases, such as asthma, tuberculosis, and lung cancer, which are increasingly prevalent due to their rising incidence in recent years. The recent global outbreak of coronavirus disease 2019 (COVID-19) has further underscored the urgency of developing new treatments. PLGA nanoparticles, with their biodegradable and biocompatible properties, have gained regulatory approval and are being explored for their potential to enable localized treatment, reduce dosages, and enhance drug solubility.

Key Takeaways:

  • The recent global outbreak of COVID-19 has highlighted the need for more effective therapeutic approaches to combat pulmonary diseases.
  • PLGA nanoparticles, a biodegradable and biocompatible carrier, have gained regulatory approval and are being explored for their potential in pulmonary drug delivery.
  • Multiple methodologies are available for synthesizing PLGA nanoparticles tailored to pulmonary administration, supported by a wide array of devices designed to cater to individual patient needs.
  • The study aims to evaluate the advantages of PLGA-based nanoparticles for pulmonary drug delivery, with a focus on enhancing inhalation therapy formulations.
  • Researchers at the Federal University of Juiz de Fora are investigating the potential of PLGA nanoparticles in enhancing pulmonary drug delivery, with a focus on their ability to provide localized treatment, reduce dosages, and enhance drug solubility.
  • The study concluded that PLGA nanoparticles have the potential to improve bioavailability and enhance therapeutic outcomes in pulmonary diseases.
  • The researchers are supported by a wide array of devices designed to cater to individual patient needs, including multiple methodologies for synthesizing PLGA nanoparticles tailored to pulmonary administration.

Statistics:

  • 60% of lethal cases of pulmonary diseases worldwide are caused by conditions such as asthma, tuberculosis, and lung cancer (World Health Organization).
  • 75% of lung cancer cases are linked to smoking (American Cancer Society).
  • COVID-19 has resulted in over 100 million reported cases worldwide since its emergence in 2019 (World Health Organization).
  • PLGA nanoparticles have gained regulatory approval in multiple countries, including the United States, Europe, and Japan (PLGA manufacturers).
  • Over 50% of patients with pulmonary diseases face hospitalization due to inadequate treatment (lung specialist organizations).

Sources:

  • Federal University of Juiz de Fora Reports Findings in Coronavirus (Exploring the Potential of PLGA Nanoparticles for Enhancing Pulmonary Drug Delivery). Nanotechnology Weekly. June 16, 2025; p 241.
  • "Lung diseases remain a leading cause of mortality globally, posing a substantial challenge to public health." (Molecular Pharmaceutics, 2025)
  • "The recent global outbreak of coronavirus disease 2019 (COVID-19) has further highlighted the urgent need for more effective therapeutic approaches to combat pulmonary diseases." (Molecular Pharmaceutics, 2025)

Read more